GSK (LON:GSK) Shares Cross Above 200-Day Moving Average – Here’s Why

GSK plc (LON:GSK) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,448.19 ($18.21) and traded as high as GBX 1,478.50 ($18.59). GSK shares last traded at GBX 1,467.50 ($18.45), with a volume of 16,677,213 shares trading hands.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Berenberg Bank reduced their price target on shares of GSK from GBX 1,820 ($22.89) to GBX 1,600 ($20.12) and set a “buy” rating for the company in a report on Friday, November 29th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of GBX 1,805.83 ($22.71).

GSK Trading Up 0.4 %

The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The business’s 50 day moving average is GBX 1,391.65 and its two-hundred day moving average is GBX 1,448.19. The firm has a market capitalization of £59.55 billion, a P/E ratio of 23.71, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Analysts expect that GSK plc will post 175.980975 EPS for the current year.

Insiders Place Their Bets

In other news, insider Jonathan Symonds purchased 1,500 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were acquired at an average price of GBX 1,315 ($16.54) per share, for a total transaction of £19,725 ($24,805.08). Also, insider Emma Walmsley sold 120,653 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.27), for a total transaction of £1,753,088.09 ($2,204,587.64). 1.61% of the stock is owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.